Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous PB-MNC Therapy in Diabetic Limb Ischemia
NCT00922389Phase 2Unknown
- Sponsor
- Beike Biotechnology
- Start
- Jul 2009
- Primary completion
- Jan 2010
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous G-CSF mobilized peripheral blood mononuclear cells in diabetic foot disease (DFD), critical limb ischemia (CLI), leg ulcer, sponsored by Beike Biotechnology. Status: unknown.
02
Drugs
autologous G-CSF mobilized peripheral blood mononuclear cells
03
Conditions
diabetic foot disease (DFD)critical limb ischemia (CLI)leg ulcer
Beyond the preview
Go deeper on NCT00922389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00922389.